Asthma

Atrial Fibrillation

Autoimmune Diseases

Biosimilars

Blood Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2023 PBMI Annual National Conference

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Print Subscription

eNewsletter

Articles

Researchers of a phase 3 trial aimed to determine whether statins, specifically pitavastatin, could reduce the incidence of major adverse cardiovascular events among HIV patients, as the risk of cardiovascular disease is increased in those with HIV infection.

Risk of Cardiovascular Disease Decreased in HIV Patients Who Were Treated With Pitavastatin

To maintain patient satisfaction and regulatory compliance and reduce potential clerical errors while maintaining high productivity, you can ease your staff’s burdens by automating your practice’s workflows and empower your staff to do more in less time.

Automate Your Practice's Workflows with These 5 Tools


ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.


CMS Moves Forward with Medicare Drug Price Negotiations


In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.


Takeda to Withdraw Oncology Drug Exkivity from U.S. Market

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Informations

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Covid-19

Eye Care

Spotlight

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Amid struggling providers, furloughs of essential workers, years of premium increases and record high earnings, for-profit health plans should consider options for directly helping their networks.

Profits of Publicly Traded Health Plans Surge Amid Requests for Higher Rates

Leah Dillard, B.A.

Articles